Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) Other Operating Expenses (2016 - 2025)

Jaguar Health (JAGX) has disclosed Other Operating Expenses for 11 consecutive years, with $5.3 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 61.31% to $5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.8 million through Dec 2025, up 43.14% year-over-year, with the annual reading at $13.8 million for FY2025, 43.14% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $5.3 million at Jaguar Health, up from $2.5 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $5.3 million in Q4 2025, with the low at $1.9 million in Q1 2024.
  • Average Other Operating Expenses over 5 years is $2.8 million, with a median of $2.7 million recorded in 2022.
  • The sharpest move saw Other Operating Expenses plummeted 53.12% in 2021, then soared 61.31% in 2025.
  • Over 5 years, Other Operating Expenses stood at $2.8 million in 2021, then decreased by 18.94% to $2.2 million in 2022, then grew by 15.43% to $2.6 million in 2023, then grew by 26.38% to $3.3 million in 2024, then skyrocketed by 61.31% to $5.3 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $5.3 million, $2.5 million, and $3.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.